GlaxoSmithKline's Volibris is a new endothelin receptor antagonist for the treatment of idiopathic (primary) pulmonary arterial hypertension, as well as PAH associated with connective tissue disease.
Twenty-five years after the discovery of HIV, Canadians living with the illness carry a huge stigma and social isolation, according to recent research findings.
